Evidence map›Paper›PMID 40462685›Full record

Trial reportBrain and behavior2025

Effects of a Valerian-Hops Extract Combination (Ze 91019) on Sleep Duration and Daytime Cognitive and Psychological Parameters in Occasional Insomnia: A Randomized Controlled Feasibility Trial.

Nathalie Schicktanz, Christiane Gerhards, Thomas Schlitt, Amanda Aerni, Elia Müggler, Dominique de Quervain, Andreas Papassotiropoulos, Georg Boonen, Juergen Drewe, Veronika Butterweck

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05684523 (Feasibility Study on the Use of Redormin® 500), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05684523 phase4completednot on this map

Feasibility Study on the Use of Redormin® 500 (Ze 91019) on Day-time Cognition and Quality of Life in People With Occasional Sleep Problems

TypeinterventionalSponsorMax Zeller Soehne AGRan2023 to 2023Enrolled40ConditionsSleep Disorders, Circadian Rhythm, Cognitive DysfunctionArmsValerian-Hop Extract, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nathalie SchicktanzDivision of Cognitive Neuroscience, Department of Biomedicine, University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-6049-6306
Christiane GerhardsDivision of Cognitive Neuroscience, Department of Biomedicine, University of Basel, Basel, Switzerland.
Thomas SchlittResearch Cluster Molecular and Cognitive Neurosciences, Department of Biomedicine, University of Basel, Basel, Switzerland.
Amanda AerniDivision of Cognitive Neuroscience, Department of Biomedicine, University of Basel, Basel, Switzerland.
Elia MügglerDivision of Cognitive Neuroscience, Department of Biomedicine, University of Basel, Basel, Switzerland.
Dominique de QuervainDivision of Cognitive Neuroscience, Department of Biomedicine, University of Basel, Basel, Switzerland.
Andreas PapassotiropoulosResearch Cluster Molecular and Cognitive Neurosciences, Department of Biomedicine, University of Basel, Basel, Switzerland.
Georg BoonenMax Zeller Soehne AG, Medical Department, Romanshorn, Switzerland.
Juergen DreweMax Zeller Soehne AG, Medical Department, Romanshorn, Switzerland.
Veronika ButterweckMax Zeller Soehne AG, Medical Department, Romanshorn, Switzerland.

Funding

Max Zeller Söhne AG
6 · The paper itself

Abstract

OBJECTIVE/

backgroundThis study evaluated the feasibility of investigating the effect of a valerian and hops-based herbal medication (Ze 91019) on daytime cognitive performance, psychological parameters, and sleep measures in individuals with occasional sleep problems.

methodsA randomized, double-blind, placebo-controlled study was conducted in 40 participants over a 21-day run-in period and a 21-day treatment period. Participants used Fitbit sleep trackers and completed daily online cognitive tests (i.e., reaction time and working memory), and surveys to assess subjective psychological outcomes (i.e., cognitive performance, stress levels, tiredness, mood, quality of life, and motivation).

resultsThe study design proved feasible, with high adherence to the study protocol. Exploratory analyses revealed a statistically significant increase in sleep duration during the treatment period for participants using Ze 91019 compared to placebo (mean daily increase: 21.7 min, p = 0.019) without statistically significant effects on cognitive or psychological outcomes. Moreover, Ze 91019 statistically significantly increased the sleep duration of the shortest night in the treatment period by 48.7 minutes. The medication was well-tolerated.

conclusionsThe study design proved feasible, and Ze 91019 increased sleep duration without affecting daytime cognitive or psychological outcomes.

trial registrationThe trial has been preregistered at www. CLINICALTRIALS: gov (NCT05684523).

Indexed as

CognitionHumulusPlant ExtractsSleepSleep Initiation and Maintenance DisordersValerianAdultDouble-Blind MethodFeasibility StudiesFemaleHumansMaleMiddle AgedQuality of LifeSleep DurationTreatment OutcomePlant Extractscognitionfeasibility studyfitbit charge 5herbal medicinehopsredorminsleepvalerianZe 91019

Identifiers

PMID40462685
PMCPMC12134488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.